Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response
Mihnea P. Dragomir, … , Sai-Ching Yeung, George A. Calin
Mihnea P. Dragomir, … , Sai-Ching Yeung, George A. Calin
Published June 1, 2023
Citation Information: J Clin Invest. 2023;133(14):e158348. https://doi.org/10.1172/JCI158348.
View: Text | PDF
Research Article Immunology Infectious disease

Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

  • Text
  • PDF
Abstract

Sepsis remains a leading cause of death for humans and currently has no pathogenesis-specific therapy. Hampered progress is partly due to a lack of insight into deep mechanistic processes. In the past decade, deciphering the functions of small noncoding miRNAs in sepsis pathogenesis became a dynamic research topic. To screen for new miRNA targets for sepsis therapeutics, we used samples for miRNA array analysis of PBMCs from patients with sepsis and control individuals, blood samples from 2 cohorts of patients with sepsis, and multiple animal models: mouse cecum ligation puncture–induced (CLP-induced) sepsis, mouse viral miRNA challenge, and baboon Gram+ and Gram– sepsis models. miR-93-5p met the criteria for a therapeutic target, as it was overexpressed in baboons that died early after induction of sepsis, was downregulated in patients who survived after sepsis, and correlated with negative clinical prognosticators for sepsis. Therapeutically, inhibition of miR-93-5p prolonged the overall survival of mice with CLP-induced sepsis, with a stronger effect in older mice. Mechanistically, anti–miR-93-5p therapy reduced inflammatory monocytes and increased circulating effector memory T cells, especially the CD4+ subset. AGO2 IP in miR-93–KO T cells identified important regulatory receptors, such as CD28, as direct miR-93-5p target genes. In conclusion, miR-93-5p is a potential therapeutic target in sepsis through the regulation of both innate and adaptive immunity, with possibly a greater benefit for elderly patients than for young patients.

Authors

Mihnea P. Dragomir, Enrique Fuentes-Mattei, Melanie Winkle, Keishi Okubo, Recep Bayraktar, Erik Knutsen, Aiham Qdaisat, Meng Chen, Yongfeng Li, Masayoshi Shimizu, Lan Pang, Kevin Liu, Xiuping Liu, Simone Anfossi, Huanyu Zhang, Ines Koch, Anh M. Tran, Swati Mohapatra, Anh Ton, Mecit Kaplan, Matthew W. Anderson, Spencer J. Rothfuss, Robert Silasi, Ravi S. Keshari, Manuela Ferracin, Cristina Ivan, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Constantin Georgescu, Pinaki P. Banerjee, Rafet Basar, Ziyi Li, David Horst, Catalin Vasilescu, Maria Teresa S. Bertilaccio, Katayoun Rezvani, Florea Lupu, Sai-Ching Yeung, George A. Calin

×

Figure 3

Effect of anti–miR-93-5p therapy in the CLP-induced sepsis model.

Options: View larger image (or click on image) Download as PowerPoint
Effect of anti–miR-93-5p therapy in the CLP-induced sepsis model.
(A) Tw...
(A) Twenty-four hours before CLP-induced sepsis, male and female C57BL/6 mice of different ages were treated i.p. with scrambled miRNA or anti–miR-93-5p. The treatment was repeated 2 hours after the induction of sepsis. Mice were followed up for 72 hours after CLP. (B) Plasma levels of miR-93-5p in septic mice treated with scrambled miRNA (n = 6) compared with septic mice treated with anti–miR-93-5p (n = 6). (C) Tissue levels of miR-93-5p in mice with sepsis treated with scrambled miRNA (n = 6) compared with septic mice treated with anti–miR-93-5p (n = 7) in organs frequently affected by sepsis: liver, heart, and kidney. (D) Pro- and antiinflammatory cytokine levels in anti–miR-93-5p–treated mice relative to levels in mice treated with scrambled miRNA. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001, by 2-tailed Student’s t test (B–D). (E) Kaplan-Meier survival analysis for 4.5-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 6). (F) Kaplan-Meier survival analysis for 8-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 7). (G) Kaplan-Meier survival analysis for 16-month-old CLP-induced septic mice treated with scrambled miRNA (n = 6) versus CLP-induced septic mice treated with anti–miR-93-5p (n = 9). (H) Kaplan-Meier survival analysis for all CLP-induced septic mice treated with scrambled miRNA together (n = 18) versus all CLP-induced septic mice treated with anti–miR-93-5p together (n = 22).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts